SEARCH

[November 03, 2009]

Here It Here First!! Sign Up For Our Free Newsletter!! (OTCBB: TNUS - Total Nutraceutical Solutions) "Total Nutraceutical Solutions Enters Into Agreement With Model Biosystems to Test Proprietary Mushroom Compounds in Suppressing Alzeheimer's Disease"

(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: TNUS - Total Nutraceutical Solutions) (NASDAQ: UNDT - Universal Detection Technology) (NASDAQ: ALNY - Alnylam Pharmaceuticals, Inc.) (NASDAQ: XXIA - Ixia) (NASDAQ: AMED - Amedisys, Inc.) (NASDAQ: SLXP - Salix Pharmaceuticals, Ltd.) www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! info@StockMarketingInc.com or call 1-866-583-8960 ---------------------------------------------------------------------------------------------------------------------------------------------- -------------- (OTCBB: TNUS - Total Nutraceutical Solutions) LATEST NEWS!! Total Nutraceutical Solutions Enters Into Agreement With Model Biosystems to Test Proprietary Mushroom Compounds in Suppressing Alzeheimer's Disease STEVENSON, Wash., Nov 01, 2009 -- Total Nutraceutical Solutions, Inc. (TNS) (OTCBB:TNUS), announced today that the company has started evaluating several proprietary mushroom compounds for activity in controlling the development of Alzheimer's Disease (AD). TNS was informed by Model Biosystems, Inc. (MBS), San Clemente, CA, that a recent experiment in Drosophila melanogaster flies (Drosophila) showed that certain TNS proprietary mushrooms had unusual anti-inflammatory activity. MBS was of the opinion that TNS should evaluate these mushroom samples in a special MBS biologic model for Alzheimer's disease (AD). This proprietary AD model uses a genetic mutant of Drosophila that was developed in the laboratory of Dr. Krishna Bhat, University of Texas, Galveston, Texas. This unique live model system can evaluate the activity of a given compound/ingredient in controlling biologic reactions and compounds that are associated with the development of human AD. The organic whole food mushrooms developed by TNS are being studied, pursuant to a signed research agreement, dated Friday, October 30, 2009, in a double-blinded investigator protocol; the total study will involve over 1,000 Drosophila with 120 organisms in each test group.

Story continues below ↓

Drosophila melanogaster, or fruit-fly is widely used in scientific and medical research. Its importance for human health was recognized by the award of the Nobel Prize for medicine in 1995, for work on the genetic control of early embryonic development. Mutant flies with defects in any of several thousand genes are available, and the entire genome has recently been sequenced. Drosophila helped in the development of drugs to combat pathogens responsible for a range of diseases from skin infections to pneumonia and meningitis. Recent research with fruit-flies has focused on the pathology of Alzheimer's disease, particularly because of the similarity between human and fly brains and the conservation of the AD genetic pathway.

"The discovery and development of organic whole foods that positively impact or help prevent diseases are welcome breakthroughs in healthcare, as more and more people demand natural alternatives to prevent disease," stated Marvin S. Hausman MD, CEO, TNS. "We believe that the unique, proprietary technology developed by TNS and used in the production of our natural organic specialty mushrooms, contributes significantly to the potential success of this new Alzheimer's disease study to be undertaken by TNS and MBS." "I am pleased that MBS is able to offer TNS the services of our biotechnology testing in their research and development of natural organic mushrooms for alternative medical approaches to preventing human diseases," stated Malli Varanasi, President, MBS. "Alzheimer's disease is a terrible human affliction and new preventative measures would be well-received by all people." About Model Biosystems, Inc.: Model Biosystems is a U.S.-based research center - company interested in harnessing the power of biotechnology for the benefit of humankind.

Our main facilities are located on the Veterinary School campus of the University of Agricultural Sciences in Bangalore, an IT and Biotechnology hub, popularly known as the Silicon Valley of India. The primary goal of Model Biosystems is to offer services to the scientific community in the area of model systems, which will serve to advance our understanding of the genetic regulation of normal development and diseases affecting humans. The knowledge thus obtained can be used to discover new drugs to cure various types of genetic diseases About Total Nutraceutical Solutions, Inc.: Total Nutraceutical Solutions, Inc. (TNS), is an emerging nutraceutical company with a focus on discovering, formulating and marketing products composed primarily of organic natural mushroom compounds that contain bioactive nutrients for potential health benefits. TNS develops production and analytic technologies for food and nutritional supplements composed primarily of mushrooms and their mycelial biomasses. Novel clinical models and biomarkers are used to show nutritional and clinical efficacy of our products. In addition to preventative healthcare formulations and nutritional approaches to a wide variety of human conditions and illnesses, TNS also develops and acquires breakthrough nutritional tools and products in the fields of animal husbandry and livestock feeds.

---------------------------------------------------------------------------------------------------------------------------------------------- -------------- (NASDAQ: UNDT - Universal Detection Technology) LATEST NEWS!! Universal Detection Technology Brings Anthrax Detection Kits and Bioterrorism Prevention Training to Milipol Paris 2009 Recent Report by U.S. Led Commission on Prevention of Weapons of Mass Destruction Proliferation and Terrorism Reveals Growing Threat of Bio-Weapons; International Security Community to Witness Latest in First Responder Technology LOS ANGELES, CA, Oct 30, 2009 -- Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that it will showcase the latest developments in bio-weapons detection technology, including the TS-10-5-agent biodetection kit, at Milipol Paris 2009.

"Our presence at Milipol comes at a time when international security experts are admonishing government agencies to be prepared for the real threat of a bioterrorism attack," said Jacques Tizabi, CEO of Universal Detection Technology. "Bio-weapon detection should be a top priority for all public entities, because for terrorists, they can be purchased or engineered at relatively low costs, can induce mass casualties and are oftentimes undetected by on-the-ground law enforcement," continued Tizabi.

The Commission on Prevention of Weapons of Mass Destruction Proliferation and Terrorism, assembled by the United States Congress post 9/11, issued an interim report last week that called bioterrorism the "most urgent threat" facing the United States. The report said that national security for anti-bioterrorism programs and "appropriate disease surveillance" were severely underfunded and neglected.

"There are bio-weapon monitoring tools immediately available for public and private entities, easy to implement and cost effective," said Tizabi. "Universal Detection Technology's biodetection kits are the first step in meeting the needs of bioterrorism prevention and planning," continued Tizabi.

Universal Detection Technology's kits, certified earlier this year by the U.S. Department of Homeland Security as an "Approved Product for Homeland Security," are the industry's only hand-held assay designed to detect and identify up to five separate threats using one sample in a single, easy-to-use device. The kits equip first responders with an effective tool for the rapid onsite detection of up to five biological warfare agents: anthrax, ricin, botulinum toxin, Y. pestis (plague) and Staphylococcal Enterotoxin B (SEB). Detection time is under three minutes.

Universal Detection Technology will showcase its TS-10-5-agent biodetection kit with live and taped demonstrations at booth #11K059 at Milipol Paris 2009, held November 17 - 21, 2009. Members of UNDT's executive team, including R&D and business development, will be present to answer questions about the products and the company.

Prior to Milipol Paris 2009, Universal Detection Technology will be presenting its biodetection kits to the 2012 London Olympics organizers at the 2009 Terrorism & Security Conference, to be held in London November 17th and 18th.

UNDT has also recently signed agreements with the U.S. Department of Commerce to be the featured exporter of bioterrorism detection equipment in France and South Korea.

For more information, please visit www.udetection.com or email info@udetection.com.

---------------------------------------------------------------------------------------------------------------------------------------------- -------------- (NASDAQ: ALNY - Alnylam Pharmaceuticals, Inc.) LATEST NEWS!! Alnylam Presents New Pre-Clinical Data on ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis -- New Data Demonstrate Durable In Vivo Efficacy for ALN-TTR -- CAMBRIDGE, Mass., Nov 02, 2009 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases ("The Liver Meeting"). Alnylam is developing ALN-TTR, a systemically delivered RNAi therapeutic targeting the TTR gene for the treatment of ATTR, including familial amyloidotic cardiomyopathy (FAC) and familial amyloidotic polyneuropathy (FAP). There are more than 100 mutations that have been identified in the TTR gene. ALN-TTR targets a region of the gene common to wild-type and all known mutant forms of TTR, and therefore, has potential as a therapeutic for all patients with FAC and FAP.

"We are very encouraged by these significant and important pre-clinical findings, which continue to validate the potential benefit of an RNAi therapeutic targeting TTR for the treatment of ATTR," said Dinah Sah, Ph.D., Vice President, Research, CNS and Oncology at Alnylam. "Our new in vivo studies represent a significant step forward as they demonstrate the ability of ALN-TTR to silence the TTR gene for a period of weeks after a single dose administration. These data provide continued validation of our RNAi therapeutics strategy, and we are looking forward to advancing this program towards the clinic." The new pre-clinical research findings presented at the meeting demonstrated dose-dependent ALN-TTR reduction of liver TTR messenger (mRNA) and serum TTR protein levels by greater than 80% in transgenic mice and non-human primates, with gene silencing effects found to be durable for more than three weeks following a single dose administration.

"I am quite excited by these new data, which strongly support the advancement of this program towards patients who have extremely limited therapeutic options," said Maria Joao Saraiva, Ph.D., Professor of Biochemistry, Molecular Neurobiology Group, Institute for Molecular and Cellular Biology in Portugal. "ATTR, which presents severe manifestations in both FAP and FAC, is estimated to affect approximately 50,000 people worldwide and is associated with significant morbidity, including intractable peripheral sensory neuropathy, disabling dysfunction of the autonomic nervous system that leads to severe intestinal dysfunction, and in many cases severe cardiomyopathy." Alnylam expects to file regulatory applications for ALN-TTR by the end of 2009 with a goal of initiating a Phase I clinical trial in early 2010. ALN-TTR is being advanced using stable nucleic acid-lipid particles (SNALP) delivery technology in collaboration with Tekmira Pharmaceuticals Corporation.

---------------------------------------------------------------------------------------------------------------------------------------------- -------------- (NASDAQ: XXIA - Ixia) LATEST NEWS!! Ixia Completes Acquisition of Agilent Technologies' N2X Data Network Testing Product Line Acquisition Further Extends Ixia's Market Leadership in Global Converged IP Network Testing CALABASAS, Calif., Nov 02, 2009 -- Ixia (Nasdaq:XXIA) a leading, global provider of converged IP performance test systems, announced today that it has completed the acquisition of the Agilent Technologies, Inc. (NYSE:A) N2X Data Networks Product Line for approximately $44 million in cash and the assumption of certain liabilities. The acquisition was structured as an asset purchase and closed on Friday, October 30, 2009.

In addition to strong broadband and carrier access protocol expertise, the N2X is known in the industry for its intuitive and powerful user interface and excellent quality. With a leadership position in high speed Ethernet (10/40/100 Gbps) IP testing, Ixia will leverage the N2X products and customer base to further penetrate markets, particularly service providers and other customers in the EMEA and Asia/Pac regions.

Ixia will continue to enhance, develop and support the N2X product line through 2015. Existing N2X customers will be able to take immediate advantage of Ixia's extreme scalability, higher speed Ethernet support, and layer 4-7 application testing through the company's Fusion initiative. Details of the Fusion program are available at www.ixiacom.com/Fusion.

About Ixia Ixia is the leading provider of converged IP performance test systems and service verification platforms for wireless and wired infrastructures and services. Ixia's test systems are used by network and telephony equipment manufacturers, semiconductor manufacturers, service providers, governments and enterprises to validate the performance and reliability of complex networks, devices and applications. Ixia's multiplay test systems address the growing need to test voice, video and data services and network capability under real-world conditions.

---------------------------------------------------------------------------------------------------------------------------------------------- -------------- (NASDAQ: AMED - Amedisys, Inc.) LATEST NEWS!! medisys Releases Report from Marwood Group Advisory BATON ROUGE, La., Nov 02, 2009 -- Amedisys, Inc. (NASDAQ: AMED)(the "Company"), one of America's leading home health and hospice nursing companies, today released the results of a review conducted by Marwood Group Advisory, LLC (Marwood). Several months ago Amedisys engaged Marwood, one of the nation's preeminent health care consulting firms, to provide an independent analysis of the Company's procedures, controls, clinical infrastructure, corporate compliance processes, technology offerings and future strategies. Marwood conducted a review of academic research, over 11,000 pages of Company specific documents, interviews with 18 members of Company leadership, and interviews with a cross section of other home health providers from across the nation, and utilized its home health industry, legislative and regulatory knowledge to measure industry standards, best practices and leading practices to evaluate the Amedisys model and infrastructure. The results showed that Amedisys ranked highest compared to other publicly traded home health companies in terms of quality improvement and compliance processes. Among their findings, Marwood stated, "Amedisys also employs best practices in the areas of field clinician coding and accuracy, oversight and management infrastructure, corporate compliance, and care coordination technology." They further state, "Based on our Quality and Compliance Process Scorecard and information collected during our review of Company documentation and onsite interviews, Marwood believes that, overall, Amedisys has implemented compliance and quality improvement processes that meet and/or exceed the industry average." The entire report has been posted to our website at www.amedisys.com.

"We are pleased with the results that Marwood found in their review of our Company," stated William F. Borne, Chief Executive Officer. "We operate our Company with a view toward providing clinical excellence for our patients while maintaining effective compliance and controls, and these findings evidence our leadership in these and other measures." Marwood Group Advisory, LLC and its affiliated companies (Member FINRA and SIPC) is a nationally recognized healthcare advisory and financial services firm headquartered in New York City with additional offices in Washington DC and London. Marwood has over 90 employees including former senior White House staff, federal agency leaders (including CMS, FDA, HHS and AHRQ) and congressional committee staff members as well as former senior healthcare operators from health plans and hospitals, former employees of state agencies, and former management consultants who monitor and analyze issues related to healthcare. Marwood provides specialized analysis for corporations, financial sponsors and other investors looking to evaluate the regulatory and reimbursement framework and risks associated with making direct investments in healthcare services, life sciences, and devices.

Amedisys, Inc. is headquartered in Baton Rouge, Louisiana. Its common stock trades on the NASDAQ Global Select Market under the symbol "AMED." ---------------------------------------------------------------------------------------------------------------------------------------------- -------------- (NASDAQ: SLXP - Salix Pharmaceuticals, Ltd.) LATEST NEWS!! Salix Pharmaceuticals Reviews American Association for the Study of Liver Diseases Annual Meeting Data Demonstrate Protective Effect and Durability of Rifaximin for Maintenance of Remission of Hepatic Encephalopathy BOSTON, Nov 02, 2009 --Data Demonstrate Rifaximin Significantly Improved Critical Flicker Frequency and Time-Weighted CFF Correlated with Overt Hepatic Encephalopathy Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announces that the 60th Annual Meeting of the American Association for the Study of Liver Diseases is the venue for two presentations describing the investigation of rifaximin for the maintenance of remission from hepatic encephalopathy. The Liver Meeting(R) is being held in Boston, Saturday, October 31 -- Tuesday, November 3, 2009.

The Protective Role of Rifaximin (550 mg tablet, 1100 mg daily) from Hepatic Encephalopathy Observed in a Double-Blind Placebo-Controlled Study is Substantiated and Durable Over the Long Term (Poster Presentation # 305, F. Poordad, et al.) Dr. Fred Poordad and colleagues presented the results of an analysis of the protective effect and the durability analyses of rifaximin treatment in the maintenance of remission in hepatic encephalopathy (HE) in an open label maintenance study (OLM). A randomized, double-blind trial (RCT) of 299 subjects demonstrated that rifaximin 550 mg BID significantly reduced the risk of a breakthrough HE episode by 57.9% (p<0.0001) in cirrhotic patients with a history of two or more overt HE episodes (Conn score equal to or greater than two) within 12 months before study enrollment. Subjects from the RCT, as well as new subjects (with a history of one or more HE episodes with Conn score equal to or greater than two within 12 months), were enrolled in the OLM. Patients received 550 mg rifaximin BID and lactulose use was permitted.

Breakthrough HE as defined as an increase to a Conn score equal to or more than two; or, if the baseline Conn score was zero, an increase of 1 each in Conn score and asterixis grade. In the OLM 266 patients had post baseline data (70 rifaximin and 82 placebo patients from the RCT and 114 new patients.) In the OLM rifaximin demonstrated a significantly protective effect (p<0.0001) compared to prior placebo experience in the time to first HE breakthrough for the 82 placebo patients from the RCT. Additionally, the estimates of time to first HE breakthrough for the 196 patients new to rifaximin (114 new plus 82 PBO from RCT) were equivalent to estimates of time for patients who had HE breakthrough in the RCT rifaximin group. 60 rifaximin patients who maintained remission throughout the RCT were followed in the OLM for up to 680 days of rifaximin therapy with a mean exposure of 482 days.

"Phase 3 study results have clearly demonstrated that rifaximin is effective in the treatment of hepatic encephalopathy (HE)," said Fred Poordad, M.D., Chief of Hepatology and Liver Transplantation at the Comprehensive Transplant Center at Cedars-Sinai Medical Center in Los Angeles. "The data from this particular analysis further substantiate the highly significant protective effect of rifaximin in minimizing breakthrough HE episodes and show that the effect from rifaximin was durable over the long term for the maintenance of HE remission. These promising results suggest that rifaximin will be an important addition to the treatment arena of hepatic encephalopathy." Rifaximin (550 mg, twice daily) Significantly Improved Critical Flicker Frequency and Time-Weighted CFF Correlated with Overt Hepatic Encephalopathy as Assessed by Conn Score in a Six-Month Study (Poster Presentation # 306, M.R. Brown, et al.) Dr. Robert Brown and colleagues presented results of an analysis of the effect of rifaximin treatment on critical flicker frequency (CFF) response and the association between quantitative CFF results and breakthrough overt hepatic encephalopathy (HE) episodes, as assessed by Conn score (CS). This randomized, double-blind, placebo-controlled trial evaluated rifaximin 550 mg BID for six months in patients (140 rifaximin and 159 placebo) with history of two or more episodes of HE (Conn score equal or greater than two) within prior six months and were in remission (Conn score 0 or 1) at baseline. 104 patients experienced HE breakthrough episodes and 194 patients maintained remission. CFF was measured at baseline and biweekly during the study. An area under the curve analysis for CFF over time was normalized by exposure time (time- weighted average or TWA). The correlation between TWA and the presence or absence of a breakthrough HE episode was analyzed. Mean changes from baseline showed significantly improved CFF in the rifaximin group compared to placebo (p=0.0320). The difference between the frequency distributions of CFF TWA in breakthrough HE epidoses versus remission was statistically significant (p<0.0001), with a significant correlation between mean TWA and breakthrough HE episodes (p<0.0001).

"The Critical Flicker Frequency (CFF) test measures eye and brain function during visual stimulation and is known to be impaired (lower Hz) in patients with hepatic encephalopathy (HE)," said Robert S. Brown, Jr., M.D., M.P.H., Frank Cardile Professor of Medicine at the Columbia University College of Physicians and Surgeons and Chief, Division of Abdominal Organ Transplantation, New York-Presbyterian Hospital, New York.

"The CFF test independently predicted breakthrough HE occurrences which underscores the utility of quantitative CFF results in predicting and managing breakthrough overt HE. The study results demonstrate rifaximin therapy significantly improved CFF performance versus placebo and could be used prophylactically to prevent breakthrough HE." About Hepatic Encephalopathy Hepatic encephalopathy (HE) is a neurological disorder caused by chronic liver failure resulting in cognitive, psychiatric, and motor impairments.(1) The condition encompasses a wide spectrum of often reversible neuropsychiatric abnormalities caused by the inability of the liver to remove toxic products in the gut, most notably ammonia produced by bacteria.(2) When toxins reach the central nervous system, this condition can result in symptoms ranging in severity from mild cerebral function deficits to coma and characterized by disruption in sleep patterns, changes in personality and intellectual capacity, high blood ammonia levels, altered neuromuscular activity and electroencephalogram (EEG) abnormalities.(3,4) About XIFAXAN(R) (rifaximin) Rifaximin is a gut-selective antibiotic with negligible systemic absorption (<0.4%) and broad-spectrum activity in vitro against both gram- positive and gram-negative pathogens. Rifaximin has a similar tolerability profile to that of placebo.

Rifaximin tablets 200 mg, which Salix markets in the United States under the trade name XIFAXAN(R) (rifaximin) tablets 200 mg, currently is approved for the treatment of patients, 12 years of age or older, with travelers' diarrhea caused by non--invasive strains of Escherichia coli.

XIFAXAN (rifaximin) is a gut--selective antibiotic with negligible systemic absorption (<0.4%) and broad--spectrum activity in vitro against both gram--positive and gram--negative pathogens. Rifaximin has a similar tolerability profile to that of placebo and has activity against the most common TD pathogens. XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more than 24--48 hours and alternative antibiotic therapy should be considered. In clinical trials, XIFAXAN was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (versus 19.7%), headache 9.7% (versus 9.2%), abdominal pain 7.2% (versus 10.1 %) and rectal tenesmus 7.2% (versus 8.8%).

About Salix Pharmaceuticals Salix Pharmaceuticals, Ltd., headquartered in Raleigh, NC, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete with any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.

---------------------------------------------------------------------------------------------------------------------------------------------- -------------- About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to info@m2.com)) (c) 2009 M2 COMMUNICATIONS

[ Back To it.tmcnet.com's Homepage ]